Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.3350
+0.0050 (1.52%)
At close: Jan 16, 2026
-20.24%
Market Cap143.55M
Revenue (ttm)n/a
Net Income (ttm)-18.77M
Shares Out428.52M
EPS (ttm)-0.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume604,008
Average Volume861,036
Open0.3350
Previous Close0.3300
Day's Range0.3300 - 0.3350
52-Week Range0.2550 - 0.6600
Beta0.30
RSI48.11
Earnings DateFeb 25, 2026

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.